



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### Purevax RC Lyophilisate and Solvent for Suspension for Injection

|                    |  |
|--------------------|--|
| • 03 November 2022 | Editorial change of the range for osmolality for stabiliser 49 to 320–356 mOsm/kg.   |
| • 18 August 2022   | Deletion of a manufacturer of an active substance.   |
| • 16 August 2022   | Modification of the conductivity test limit of acceptance carried out on sterile diluent to less than or equal to 25 µS/cm.  |
| • 05 August 2022   | To increase the maximum release titre of the feline herpesvirus component of Purevax vaccines from 10 <sup>6.2</sup> CCID50/dose to 10 <sup>6.5</sup> CCID50/dose and to align the titre across the documents to be expressed in units/dose. |
| • 06 May 2022      | Changes to SPC & product literature following a periodic safety update report (PSUR)   |
| • 17 March 2022    | Change of a test procedure for the active substance.<br>Changes in the manufacturing process of the active substance.  |
| • 25 June 2021     | Addition of a new specification parameter to the specification with its corresponding test method of the finished product.<br>Deletion of a non-significant specification parameter of the finished product.                                 |
| • 26 March 2021    | Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.   |